DEM BioPharma
Cambridge, MA
DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.
dembiopharma.comCompany Details
Founded
- 2022
Employees
- Between 20 - 50 employees
Raised
- $70,000,000
Headquarters Location
- Cambridge, MA
Public
- No
Acquired
- No
CEO
Nenad Grmusa
Founders
- Christoph WestphalDavid DonabedianKipp WeiskopfJohn Pribis
Company Collections
These are collections DEM BioPharma is a part of. Click on the collection name to view similar companies.
DEM BioPharma's Industries
DEM BioPharma Headquarters Location
Cambridge, MA 02138
Total Amount Raised: $70,000,000
DEM BioPharma Funding Rounds
Series A
$70,000,000
Series A Investors
Alta PartnersLongwood FundInsight Venture PartnersAlexandria Real Estate EquitiesAstellas Venture ManagementPfizer Venture InvestmentsUTokyo Innovation Platform Co.Emerson Collective
Funding info provided by Diffbot.
DEM BioPharma Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on DEM BioPharma.